AlphaCentric Advisors LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 491 shares of the biopharmaceutical company's stock, valued at approximately $350,000.
Several other hedge funds have also added to or reduced their stakes in the business. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. Private Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 39 shares during the last quarter. Finally, Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. 83.31% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the stock. Citigroup lowered their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a report on Tuesday, February 4th. Finally, Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.
Get Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Up 1.5 %
REGN stock traded up $10.36 on Thursday, reaching $696.02. 627,485 shares of the company traded hands, compared to its average volume of 929,462. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a fifty day simple moving average of $700.92 and a 200-day simple moving average of $887.66. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company has a market cap of $76.09 billion, a P/E ratio of 18.18, a price-to-earnings-growth ratio of 2.28 and a beta of 0.08.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $11.86 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.
Regeneron Pharmaceuticals Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.51%.
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
